Dr. Rippee is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
3599 Rainbow Blvd
Kansas City, KS 66103- Is this information wrong?
Education & Training
- University of Kansas School of MedicineFellowship, Vascular Neurology, 2011 - 2012
- University of Kansas School of MedicineResidency, Neurology, 2008 - 2011
- University of Missouri Kansas City School of MedicineClass of 2007
Certifications & Licensure
- KS State Medical License 2011 - 2024
- American Board of Psychiatry and Neurology Neurology
- American Board of Psychiatry and Neurology Vascular Neurology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
Clinical Trials
- Ghrelin (OXE--103) for Acute Concussion Management Start of enrollment: 2020 Oct 20
Publications & Presentations
PubMed
- Evaluating olfactory function and quality of life in patients with traumatic brain injury.Amelia S Lawrence, Rahul Alapati, Sarah F Wagoner, Antonio Bon Nieves, Cole Bird, Robert Wright, Shah Jafri, Michael Rippee, Jennifer A Villwock> ;International Forum of Allergy & Rhinology. 2024 Apr 14
- 1 citationsAssessing Cognitive Behavioral Therapy for Insomnia to Improve Sleep Outcomes in Individuals With a Concussion: Protocol for a Delayed Randomized Controlled Trial.Rebecca Ludwig, Michael Rippee, Linda J D'Silva, Jeff Radel, Aaron M Eakman, Jill Morris, Michelle Drerup, Catherine Siengsukon> ;JMIR Research Protocols. 2022 Sep 23
- 2 citationsChallenging the Vestibular System Affects Gait Speed and Cognitive Workload in Chronic Mild Traumatic Brain Injury and Healthy Adults.Linda D'Silva, Prabhakar Chalise, Michael Rippee, Hannes Devos> ;Frontiers in Neurology. 2022 Jan 1
- Join now to see all
Press Mentions
- Oxeia Announces Positive Interim Results of Phase 2 Trial for oxe103 for the Treatment of ConcussionsAugust 3rd, 2022
- Symptoms You May Experience After Getting a COVID-19 VaccineJanuary 5th, 2021
- Oxeia Biopharmaceuticals, Inc. Announces Initiation of Phase 2 Trial for OXE103 for the Treatment of ConcussionsOctober 21st, 2020
- Join now to see all
Hospital Affiliations
- The University of Kansas HospitalKansas City, Kansas
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: